共 76 条
- [1] Andes D., Pascual A., Marchetti O., Antifungal therapeutic drug monitoring: Established and emerging indications, Antimicrob Agents Chemother, 53, pp. 24-34, (2009)
- [2] Lewis R.E., What is the "therapeutic range" for voriconazole?, Clin Infect Dis, 46, pp. 212-214, (2008)
- [3] Schumacher G.E., Introduction to therapeutic drug monitoring, Therapeutic Drug Monitoring, pp. 1-17, (1995)
- [4] Walsh T.J., Teppler H., Donowitz G.R., Et al., Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia, N Engl J Med, 351, pp. 1391-1402, (2004)
- [5] Walsh T.J., Pappas P., Winston D.J., Lazarus H.M., Petersen F., Raffalli J., Yanovich S., Stiff P., Greenberg R., Donowitz G., Schuster M., Reboli A., Wingard J., Arndt C., Reinhardt J., Hadley S., Finberg R., Laverdiere M., Perfect J., Garber G., Fioritoni G., Anaissie E., Lee J., Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever, New England Journal of Medicine, 346, 4, pp. 225-234, (2002)
- [6] Walsh T.J., Finberg R.W., Arndt C., Hiemenz J., Schwartz C., Bodensteiner D., Pappas P., Seibel N., Greenberg R.N., Dummer S., Schuster M., Holcenberg J.S., Dismukes W.E., Liposomal amphotericin b for empirical therapy in patients with persistent fever and neutropenia, New England Journal of Medicine, 340, 10, pp. 764-771, (1999)
- [7] Drutz D.J., Spickard A., Rogers D.E., Koenig M.G., Treatment of disseminated mycotic infections: A new approach to amphotericin B therapy, Am J Med, 45, pp. 405-418, (1968)
- [8] Hong Y., Shaw P.J., Nath C.E., Yadav S.P., Stephen K.R., Earl J.W., McLachlan A.J., Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases, Antimicrobial Agents and Chemotherapy, 50, 3, pp. 935-942, (2006)
- [9] Brammer K.W., Farrow P.R., Faulkner J.K., Pharmacokinetics and tissue penetration of fluconazole in humans, Reviews of Infectious Diseases, 12, SUPPL. 3, (1990)
- [10] Rex J.H., Pfaller M.A., Galgiani J.N., Bartlett M.S., Espinel-Ingroff A., Ghannoum M.A., Lancaster M., Odds F.C., Rinaldi M.G., Walsh T.J., Barry A.L., Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections, Clinical Infectious Diseases, 24, 2, pp. 235-247, (1997)